There's a simple explanation for the haste with which the Senate is moving to pass a law that will have devastating consequences for the health of the tens of millions of Americans. They need the money.
President Donald Trump seems to be changing his mind about the House-passed version of the American Health Care Act.
Will Pfizer and the other major drug manufacturers pay a price in Washington for willfully ignoring the national imperative to keep healthcare costs under control?
As Republican senators rethink the American Health Care Act, a more pressing question looms, will they stabilize the individual insurance market for 2018?
Anyone who knows anything about healthcare didn't need a CBO scorecard to understand the disastrous consequences of the American Health Care Act.
Trump administration undercuts its plans to battle opioid addiction with conflicting messages and policies.
Healthcare systems have come a long way using their medical records and claims data to flag patients at high risk of contracting chronic diseases such as diabetes. Unfortunately, under fee-for-service medicine, doing something with that information is rarely a smart move financially.
Payment reform won't change the graying of America. But it is exactly what the doctor ordered to deal with the outrageously high prices and overutilization of questionable technologies that plague the entire system.
Politics, like nature, abhors a vacuum. Witness how the pharmaceutical industry has succeeded in taking advantage of President Donald Trump's failure to do something—anything—about high drug prices.
It's time to check in with the governing party to see how its plan to replace Obamacare is progressing.
Our Editorial Code of Ethics, which is regularly updated and also can be found under the "About Us" section of ModernHealthcare.com, offers the parameters under which we work.
Dr. Scott Gottlieb is by far the most conflicted person nominated to run the 111-year-old Food and Drug Administration. If the Office of Government Ethics was doing its job, it wouldn't let him near the commissioner's chair for at least a year.